In the financial year to March 2025, a specialty-chemicals platform that had been trading for barely 18 months reported operating revenue of ₹200 crore (about $21 million at ₹96.0 to the dollar), up more than eleven times from ₹17.74 crore the year before, according to regulatory filings reported by Entrackr in July 2026. In the same year, it lost ₹25.38 crore. That is the paradox at the centre of Scimplify: one of the fastest revenue ramps in Indian B2B, paired with a loss that grew alongside the top line.
Scimplify is the brand of CoCreate Global Technologies Private Limited, a Bengaluru company incorporated on 22 September 2023 (CIN U21009KA2023PTC179006, Karnataka Registrar of Companies, per Tracxn). It sits in an unglamorous corner of the economy, the sourcing and made-to-order manufacture of specialty chemicals, and it has attracted an unusually crowded cap table for a company this young, including Accel, Bertelsmann, Omnivore, 3one4 Capital and, most recently, Japan’s Hitachi Ventures. This piece works through what the company actually does, who built it, how it earns, the three years of numbers on public record, and the risks the balance sheet already shows.
Quick facts
| Company | Scimplify (CoCreate Global Technologies Private Limited) |
| Founded | Incorporated 22 September 2023, Bengaluru (Tracxn; CIN U21009KA2023PTC179006) |
| Founders | Sachin Santhosh, Salil Srivastava, Dheeraj Dhingra (Forbes India) |
| Businesses | Full-stack B2B specialty-chemicals platform: contract research, process engineering and made-to-order manufacturing via its ATOMS platform |
| Latest FY revenue | ₹200 crore operating revenue in FY25, up 11x from ₹17.74 crore in FY24 (Entrackr, July 2026, from RoC filings) |
| Latest FY profit / loss | Net loss of ₹25.38 crore in FY25 (Entrackr, July 2026) |
| Listed | Private (no IPO as of September 2026) |
| Last valuation | About ₹2,323 crore (Entrackr estimate, July 2026) at the Hitachi Ventures-led Series C; Series B was struck at roughly $150 million post-money in March 2025 (TechCrunch) |
| Key shareholders | 3one4 Capital 15.54%, Accel 13.84%, Omnivore 12.14%, Bertelsmann 10.26%, Hitachi Ventures 3.28% (Entrackr, post-Series C) |
What Scimplify does
Scimplify is a business-to-business platform for specialty chemicals: the low-volume, high-value compounds that go into medicines, crop protection, cosmetics and industrial processes rather than into bulk commodities. It does not simply list suppliers; it takes responsibility for the whole chain from molecule to delivery. Its offering breaks into a few clear parts:
- Contract research and process engineering: an in-house R&D team of more than 50 scientists develops routes and reworks existing chemistries to make them cheaper or fit a new use case (Forbes India, 2026).
- Made-to-order manufacturing: it places production with a vetted network of third-party plants rather than owning factories, and manages quality and delivery on the buyer’s behalf (TechCrunch, March 2025).
- The ATOMS platform, which lists chemicals from more than 5,000 factories run by over 200 manufacturers across 10 countries, and gives buyers real-time traceability from R&D through to delivery (TechCrunch, March 2025).
- End sectors: pharmaceuticals, agrochemicals, personal care, life sciences and metallurgy (Entrepreneur India; Forbes India).
As of March 2025 the company said it had served 600 customers across more than 16 countries, sourcing from a supplier base spread across India, China, Vietnam, Egypt and Japan among others (TechCrunch, March 2025).
The origin
The idea did not start with a factory or a product. It started with a question. In 2022, co-founder Sachin Santhosh was talking to a pharmaceutical executive in the United States who needed a specific chemical intermediate for a drug. The compound was not exotic; a factory in Hyderabad could make it. What the American buyer could not be sure of was whether that factory could make it to the right quality, at commercial scale, and supply it reliably, month after month, as reported by Forbes India in 2026.
That gap between raw manufacturing capacity and dependable, auditable supply became the founding thesis. As Santhosh put it, the problem was not supply but trust and scalability (Entrepreneur India). India had plenty of underused chemical plants; what it lacked was a layer that could vet them, standardise quality and stand behind delivery to a global buyer. Santhosh had studied material science at IIT Madras, spent time in investment banking at Credit Suisse, and then worked at OfBusiness across polymers, textiles and packaging, which gave him a close view of how fragmented and informal Indian manufacturing supply chains can be (Entrepreneur India). He teamed up with Salil Srivastava, who had built and scaled a chemicals vertical to about $20 million in revenue at Zetwerk and holds an MBA from MANAGE Hyderabad, and Dheeraj Dhingra, an IIM Bangalore graduate who had run international markets across the Middle East and Southeast Asia at Zetwerk (Forbes India). The company was incorporated in September 2023 and, in its earliest fundraising coverage, was even spelt “Scimplifi” (Entrackr, December 2023).
The hard part: trust, not supply
Scimplify is young enough that it has no decade of near-death stories to tell. Its struggle is structural, and it is visible in the accounts. The company chose the harder version of the specialty-chemicals business: not to be a broker taking a clip on trades, but to underwrite quality and delivery end to end. That means carrying the cost and the risk of a problem the market had left unsolved.
Three concrete frictions stand out from the public record:
- Building a trust layer from scratch. Scimplify vets manufacturers, has them audited by third parties on a roughly semi-annual basis, and segments them by geography, chemistry, capacity and compliance before they can take orders (TechCrunch, March 2025). That quality infrastructure is expensive to run and does not scale as cleanly as software.
- A tiny starting base. Because it began trading only in September 2023, FY24 operating revenue was just ₹17.74 crore (Entrackr, from RoC filings). Everything about the company’s later growth rate is measured off that very small first year.
- Growth bought with losses. In FY25, the first full year of scale, the company posted a net loss of ₹25.38 crore even as revenue reached ₹200 crore (Entrackr, July 2026), a reminder that owning quality and fulfilment, rather than just matchmaking, costs money up front.
In other words, the difficulty was never finding chemicals or factories. It was persuading global buyers that an Indian-sourced, made-to-order supply chain could be as dependable as an incumbent’s, and then paying to make that promise true.
The turning point
The single event that changed Scimplify’s trajectory was its $40 million Series B on 12 March 2025, co-led by Accel and Bertelsmann India Investments, with participation from UMI, Omnivore and 3one4 Capital (TechCrunch; Entrepreneur India). It was struck at a post-money valuation of roughly $150 million (TechCrunch), and it took total capital raised to about $54 million since inception.
The numbers on either side of that round tell the story of why investors were willing to pay up. Going in, the company had a March-2024 revenue base of ₹17.74 crore. Coming out of the year in which the round landed, FY25 operating revenue had reached ₹200 crore, an eleven-fold jump in a single year (Entrackr, July 2026). At the same time the workforce roughly doubled, from about 150 employees around the time of the Series B (TechCrunch, March 2025) to 236 by August 2025 (Tracxn). The Series B was the capital that let Scimplify turn a promising thesis into an operating business at scale, and it set up the far larger valuation step that followed a year later.
The money behind it
For a company incorporated in September 2023, Scimplify has raised quickly and from a mix of Indian and global names. The rounds on record:
- Seed: $3.67 million, closed 30 November 2023, led by 3one4 Capital and BEENEXT with angel investors from the chemicals and B2B commerce industries (Entrackr, December 2023).
- Series A: about $9.5 million in 2024, led by Omnivore and Bertelsmann India Investments (Entrepreneur India; Forbes India). Tracxn dates this round to 26 July 2024.
- Series B: $40 million on 12 March 2025, co-led by Accel and Bertelsmann India Investments, at roughly $150 million post-money (TechCrunch; Entrepreneur India).
- Series C: ₹181 crore (about $19 million), reported by Entrackr on 16 July 2026, led by Hitachi Ventures with ₹76.15 crore; 3one4 Capital put in ₹31.41 crore, Accel ₹28 crore, Omnivore ₹24.55 crore and Bertelsmann Nederland ₹20.75 crore.
What the backers changed, in plain terms:
- 3one4 Capital and BEENEXT gave the company its first institutional validation and remain central; after the Series C, 3one4 is the largest external shareholder at 15.54% (Entrackr).
- Bertelsmann and Omnivore anchored the Series A and stayed through every subsequent round, signalling conviction in the agri- and industrial-chemicals angle.
- Accel co-led the Series B and holds 13.84% post-Series C (Entrackr), bringing the classic growth-stage playbook to a manufacturing-heavy business.
- Hitachi Ventures, the Series C lead, adds a strategic Japanese industrial backer as Scimplify pushes into markets such as the United States and Japan (TechCrunch).
On valuation, the contested figure worth flagging: Entrackr’s July 2026 report, drawn from regulatory filings, put the Series C valuation at about ₹2,323 crore (around $245 million on the source’s own conversion), up 114% from roughly ₹1,086 crore previously. That estimate is echoed by Ascendants, though both trace to the same filings-based analysis, so it is best read as a reported estimate rather than a company-confirmed figure. The independently reported Series B mark of about $150 million post-money (TechCrunch, March 2025) is the firmer anchor.
How it makes money
Scimplify earns by owning the transaction rather than referring it. The economics work roughly like this:
- Money in: the company sells finished, made-to-order specialty chemicals to buyers, booking the full order value as revenue rather than a thin listing fee. That is why FY25 operating revenue could reach ₹200 crore so fast (Entrackr).
- Costs out: it pays its vetted third-party plants to manufacture, and carries the cost of R&D (50-plus scientists), quality auditing and logistics. It does not own factories, which keeps fixed capital light but pushes cost into procurement and people (Forbes India; TechCrunch).
- Where the margin sits: value is added in the chemistry, the process engineering that makes a compound cheaper or fit for a new use, the quality assurance and the reliability of delivery, not in arbitraging price between a factory and a buyer.
- The part people get wrong: because it reports gross merchandise-style order revenue, the top line looks enormous relative to a marketplace that books only commissions. The FY25 net loss of ₹25.38 crore against ₹200 crore of revenue (Entrackr) shows this is a low-margin, working-capital-intensive model, closer to a managed-manufacturing business than to a software platform.
The numbers
Only two full years sit on the public record so far, because the company has been trading only since September 2023 and had not filed FY26 accounts as of Entrackr’s July 2026 report. The figures below are operating revenue and net profit or loss, in ₹ crore, as reported by Entrackr from RoC filings.
| Financial year | Operating revenue (₹ crore) | Net profit / (loss) (₹ crore) |
| FY24 (to March 2024) | 17.74 | Not separately reported |
| FY25 (to March 2025) | 200 | (25.38) |
| FY26 (to March 2026) | Not yet filed as of July 2026 | Not yet filed |
A few points of context for the table:
- The FY24-to-FY25 revenue jump is more than 11x, one of the steepest in Indian B2B, but it is measured off a first-year base of only ₹17.74 crore (Entrackr).
- Forbes India cited a slightly different FY24 figure of ₹18.3 crore; the small gap likely reflects operating versus total income, so the FY24 base should be read as roughly ₹18 crore either way.
- Tracxn independently places FY25 revenue in the ₹100–500 crore band as of 31 March 2025, consistent with Entrackr’s ₹200 crore figure.
Where the money comes from
Scimplify’s revenue is spread across end-industries and, increasingly, across borders. The disclosed splits and mix:
- End markets: pharmaceuticals, agrochemicals, personal care, life sciences and metallurgy are the named demand sectors (Entrepreneur India; Forbes India).
- Customer footprint: 600 customers across more than 16 countries as of March 2025 (TechCrunch), so a meaningful share of demand is export rather than purely domestic.
- Supply footprint: chemicals are sourced from over 5,000 factories run by more than 200 manufacturers across 10 countries, including India, China, Vietnam, Egypt and Japan (TechCrunch).
- Expansion markets: the company has been opening in the United States and Japan, pointing to where it expects future demand to concentrate (TechCrunch).
The surprise in the mix is that a company built on the pitch of “Indian manufacturing for the world” already sources from a genuinely multi-country supplier base. It is less a made-in-India story than a made-to-order-anywhere one, with India as the anchor rather than the whole map.
The risks
The public numbers already point to concrete risks, not hypothetical ones:
- Thin, negative margins. A ₹25.38 crore loss on ₹200 crore of revenue in FY25 (Entrackr) shows that booking full order value does not yet translate into profit; the model depends on either raising prices, deepening higher-margin R&D work, or squeezing procurement, none of them guaranteed.
- Working-capital and counterparty exposure. Because Scimplify takes responsibility for made-to-order production across 200-plus third-party plants (TechCrunch), it carries inventory, quality and delivery risk that a pure marketplace would push onto others; a single failed batch or defaulting plant hits its own P&L.
- Concentration on a young track record. With only two filed years and revenue growth built off a ₹17.74 crore base, the eleven-fold jump is impressive but unproven at durability; the company had not filed FY26 accounts as of July 2026 (Entrackr), so investors are valuing it at roughly ₹2,323 crore (Entrackr estimate) largely on trajectory.
The takeaway
Scimplify’s real lesson is about where value hides in an old, fragmented industry. India did not lack chemical factories; it lacked a party willing to stand behind quality, scale and delivery so a buyer in New Jersey or Tokyo could trust an order placed in Hyderabad. Scimplify chose to own that promise rather than just advertise it, and the market rewarded the harder choice with capital, a fast-rising top line and a valuation step of more than 100% in a year. The unfinished part of the lesson is on the same page of the accounts: underwriting trust is expensive, and a business that books full order value still has to prove it can turn eleven-fold growth into durable margin. The company that fills a trust gap can grow astonishingly fast; whether it can also earn is the next thing the filings will have to show.
Frequently asked questions
What does Scimplify do?
Scimplify is a business-to-business specialty-chemicals platform. It offers contract research, process engineering and made-to-order manufacturing through a vetted network of third-party plants, and lists chemicals from more than 5,000 factories on its ATOMS platform, serving sectors such as pharmaceuticals, agrochemicals and personal care (TechCrunch, March 2025; Forbes India, 2026).
Who founded Scimplify and when?
It was founded by Sachin Santhosh, Salil Srivastava and Dheeraj Dhingra, and the operating entity, CoCreate Global Technologies Private Limited, was incorporated on 22 September 2023 in Bengaluru (Forbes India; Tracxn).
How much money has Scimplify raised?
It raised a $3.67 million seed in November 2023, about $9.5 million in a 2024 Series A, a $40 million Series B in March 2025, and a ₹181 crore (about $19 million) Series C led by Hitachi Ventures reported in July 2026, taking cumulative funding to roughly $73 million (Entrackr; TechCrunch; Tracxn).
What is Scimplify’s revenue and is it profitable?
Operating revenue rose to ₹200 crore in FY25 from ₹17.74 crore in FY24, a more than eleven-fold increase, but the company posted a net loss of ₹25.38 crore in FY25 (Entrackr, from RoC filings, July 2026). It is not yet profitable.
What is Scimplify’s valuation?
Entrackr estimated the Series C valuation at about ₹2,323 crore (around $245 million on its own conversion) in July 2026, up 114% from roughly ₹1,086 crore. This is a filings-based estimate rather than a company-confirmed figure; the Series B was independently reported at about $150 million post-money in March 2025 (TechCrunch).
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Entrackr, “Scimplify set to raise Rs 181 Cr at over 2X valuation jump” — July 2026
- Entrackr, “Scimplifi raises $3.67 Mn in seed round” — December 2023
- TechCrunch, “Scimplify raises $40M to help manufacturers access specialty chemicals” — March 2025
- Forbes India, “How three founders built Scimplify to fill India’s chemical supply gap” — 2026
- Entrepreneur India, “Scimplify Secures USD 40 Mn Series B Funding” and “Chemistry of Systematic Scaling” — 2025 / 2026
- Tracxn, Scimplify company profile (entity, CIN, funding, headcount) — 2026
- Ascendants, “Scimplify to raise Rs 181 crore in Hitachi Ventures-led Series C” — July 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.